Navigation Links
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Date:8/19/2007

ofessional as a 30-minute intravenous infusion at a fixed dose based on body weight range approximating 10 mg/kg at day 0, 2 weeks, 4 weeks, and every 4 weeks thereafter. Acute infusion-related reactions were experienced in nine percent of people treated with ORENCIA and in six percent of people treated with placebo. According to the full prescribing information, the most frequently reported infusion- related adverse events (1 percent to 2 percent) were dizziness, headache, and hypertension. In pivotal studies, premedications were not required. However, appropriate medical support measures for the treatment of hypersensitivity reactions should be available for immediate use in the event of a reaction.

About ORENCIA(R) (abatacept)

ORENCIA is currently indicated in the United States for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as methotrexate or TNF antagonists. ORENCIA may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists. ORENCIA should not be administered concomitantly with TNF antagonists and is not recommended for use concomitantly with anakinra.

Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Materia Licenses Metathesis Catalyst Platform to Eisai
4. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
5. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
6. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
7. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
8. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
9. New Quality Control Systems for Every Laboratory Application
10. Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented
11. Antares Pharma Announces Positive Results from Application Site Study for Anturol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... 27, 2015 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution ... radiotherapy and diagnostic imaging centers in ... a purchase agreement under which Concord Medical Services ... the Company, agreed to acquire the Fortis Surgical ...
(Date:3/26/2015)... 26, 2015 "Whether it,s our family, our ... In a single sentence, Dr. Anthony ... at Pfizer,s Centers for Therapeutic Innovation (CTI), ... progress at America,s biopharmaceutical companies. CTI,s ... academia, patient foundations and the National Institutes of Health ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2
... 24, 2011 Apelon, Inc., a leading ... today announced the availability of the first ... code set management and collaborative mapping application, ... enabling widespread access to national healthcare vocabulary ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , for the diabetes, cancer, dermatology ... presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, ... is a PEGylated form of rHuPH20 that is being ...
Cached Medicine Technology:Apelon Announces Availability of New TermManager® Software 2Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting 2
(Date:3/27/2015)... NE (PRWEB) March 27, 2015 Ticket Down ... at the CenturyLink Center in Omaha, Nebraska on Friday, ... possibility that more concert dates will be added in Omaha ... of fan demand. , The Garth Brooks World Tour is ... the latest announcement that Garth Brooks and Trisha Yearwood will ...
(Date:3/27/2015)... Endure Yoga is launching WOD (Workout ... This new program matches yoga poses with functional fitness ... down. This program utilizes yoga to improve recovery, prevent ... , Karen Lefurgy, competitive athlete at CrossFit ... I started Crossfit® training, but quickly, due to time ...
(Date:3/27/2015)... 27, 2015 SMI (Silicon Microstructures, Inc.), ... has launched the SM1120 MEMS based ultra-miniature pressure sensor ... microsensor profile at only 220um x 75um provides ample ... challenging locations. With industry leading in vivo drift ... provides a broad operating pressure range from 0 to ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Operatic contenders ... of greatness on April 17th. The universally acclaimed baritone ... the 9th annual Opera Idol at The Merion in ... competition, which has drawn aspiring opera singers from around ... showcases some of the finest young talent in the ...
(Date:3/27/2015)... The 2015 Deep Market Research Report ... in-depth study on the current state of the ... on the Chinese situation. , The report provides ... classifications, applications and industry chain structure. The Glutathione ... and Chinese domestic situations including development trends, competitive ...
Breaking Medicine News(10 mins):Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 2Health News:Cheap Garth Brooks Tickets for CenturyLink Center in Omaha: Ticket Down Slashes Garth Brooks Concert Tickets in Omaha, NE at the CenturyLink Center 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... in our environment that may cause breast cancer . ... linked to breast cancer has listed 216 compounds, many of ... extensive review of 900 scientific studies concerning humans and rodents ... and water that appear to be a reason behind breast ...
... toll the world over. Almost 100 million girls die every year, ... ,According to a searing report on the prejudices against women, "Because ... developing countries, where a male child remains more valued. ... child development agency - highlights the fact that two million girls ...
... Researchers at University of Southern Maine in Portland have revealed ... far the US government has been denying the possibility. ... Laboratories in New Mexico found that people exposed to DU ... ,DU is a dense, inadequately radioactive metal that is ...
... of North Carolina, Chapel Hill, have found out that middle-aged ... are at a higher risk of retinopathy than others. ... of the eye that can lead to severe vision problems ... the headache history and eye health of 10,902 men and ...
... same level of active therapeutic chemical and produces the ... the harmful toxins, according to UCSF researchers. ... of the active ingredient delta-9-tertrahydrocannibinol, or THC, are reported ... and Therapeutics." ,"We showed in a recent ...
... claimed significant success in the continuing fight to develop ... ,Thomas Pento and Roger HarrisonTwo professors say ... the spread of certain cancerous cells without damaging healthy, ... in fighting lung, prostate and pancreatic cancers without the ...
Cached Medicine News:Health News:List of Compounds That Causes Breast Cancer Identified 2Health News:Female Infanticide and Feticide Continue to Increase 2Health News:History of Migraines Linked to Increased Risk of Retinopathy 2Health News:Smokeless Cannabis Delivery Device Found Efficient and Less Toxic 2Health News:US Professors Develop Fusion Protein to Fight Cancer 2
... A CMV assay for screening donors on ... CMV-PA System uses CMV antigen attached to ... cytomegalovirus. Relative sensitivity and specificity of the ... 99.8% and 99.3% respectively. The use of ...
... microplate agglutination technology. Its is a fully ... testing. PK7200 also handles weak D as ... The Automated Microplate System delivers the very ... that for the past generation has tested ...
... fully automated blood bank ... American market based on ... The ORTHO ProVue™ eliminates ... increasing productivity via random ...
... are in need of MRI exams, many ... scanners. They have heard of, or experienced ... and noisy tubes of supercon scanners - ... people want is a patient-friendly MRI. Now ...
Medicine Products: